Bufrudin
Direct thrombin inhibitor from the Asian buffalo leech — hirudin homolog described in Hirudinaria manillensis secretome.
Preclínico / mecanísticoLast updated: 2026-05-26 · Reviewed by ASH Editorial Board
Mechanistic Evidence Box
Preclinical / mechanistic- Page type
- Compound profile
- Evidence type
- Direct thrombin inhibitor from the Asian buffalo leech — hirudin homolog described in Hirudinaria manillensis secretome.
- Evidence level
- Mechanistic discussion
- Drug vs leech
- Purified natural compound
- Safety domains
- Bleeding
Clinical translation limit
Bufrudin is documented mechanistically only; no human evidence. Sequence/structural homology to hirudin does NOT establish clinical anticoagulant efficacy, and no FDA-approved derivative exists.
Molecular Profile
- Category
- Anticoagulant
- Evidence tier
- Preclinical
- Molecular weight
- 7,000 Da
- Source species
- Hirudinaria manillensis
- Discovered
- 1991
Biological Targets
- → thrombin (Factor IIa)
Key Citations
- Electricwala A et al. (1991), Blood Coagul Fibrinolysis · PMID 1773002
- Electricwala A et al. (1993), J Protein Chem · PMID 8397794
External Resources
Related Anticoagulant Compounds
Hirudin
The most potent natural thrombin inhibitor — and the molecular template for three FDA-approved direct thrombin inhibitor drugs.
Antistasin
Factor Xa inhibitor — prototype molecule that inspired the entire DOAC drug class (rivaroxaban, apixaban).
Ghilanten
Factor Xa inhibitor with anti-metastatic activity in animal cancer models — translational dual-use compound.
Lefaxin
Factor Xa inhibitor with anti-inflammatory properties.